ArticleCureus2026
Efficacy and Safety of Dexmedetomidine as an Adjuvant to Bupivacaine in Ultrasound-Guided Pericapsular Nerve Group (PENG) Block for Proximal Femoral Fractures: A Randomised, Single-Centre Controlled Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dexmedetomidine as an Adjuvant in Femoral Nerve Block for Ease of Preoperative Positioning and Postoperative Analgesia in Hip and Proximal Femur Surgery.Anesthesiology and pain medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDexmedetomidine has been used in many peripheral nerve blocks, as it enhances the duration of analgesia and hastens its onset. We compared whether adding dexmedetomidine to bupivacaine in the pericapsular nerve group (PENG) block resulted in prolonged duration of analgesia with ease of positioning for spinal anaesthesia in proximal femur fractures without adverse effects.
methodsThis prospective randomised study was conducted in a tertiary care hospital in North India between January 2024 and June 2024 after institutional ethics approval and Clinical Trials Registry of India (CTRI) registration (CTRI/2024/12/078728). Sixty adult patients aged 18-60 years, with American Society of Anesthesiologists (ASA) physical status I-III, presenting with proximal femur fractures less than seven days old and moderate to severe pain (numeric rating score (NRS) > 4), scheduled for surgery, were randomly allocated to Group A or Group B. Group A received 20 mL of 0.25% bupivacaine with 50 mcg dexmedetomidine (0.5 mL) for the PENG block, while Group B received 20 mL of 0.25% bupivacaine with 0.5 mL of saline for the PENG block. The primary outcome was the duration of analgesia. Secondary outcomes included ease of spinal positioning score, postoperative pain scores, postoperative opioid requirement, quadriceps strength at 24 hours, and adverse events.
resultsIn this single-centre trial, the use of dexmedetomidine as a perineural adjuvant in the PENG block was associated with a prolonged duration of analgesia (95% CI: 2.89-4.71; p < 0.001), better positioning scores (p < 0.001), and lower postoperative pain scores compared to bupivacaine alone in 60 patients aged 18-60 years. Motor function was preserved in both groups, and no significant adverse events were observed.
conclusionsDexmedetomidine is a safe and effective adjuvant for the PENG block in proximal femur fracture surgeries in adults aged 18-60 years. Further studies in geriatric populations are required for broader clinical recommendations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.